Loading...
•
Jul 02, 2022
Bioventus Q2 2022 Earnings Report
Reported strong growth, driven by acquisitions and organic business expansion.
Key Takeaways
Bioventus reported a net sales increase of 27.8% year-over-year to $140.3 million in Q2 2022. The company's net loss improved to ($8.0) million, and adjusted EBITDA increased to $22.9 million. The company updated its full-year 2022 financial guidance.
Net Sales of $140.3 million, up 27.8% year-over-year as reported.
Net Loss of ($8.0) million, compared to ($10.8) million in prior-year period.
Adjusted EBITDA of $22.9 million, compared to $19.9 million in prior-year period.
Non-GAAP earnings per share of Class A common stock of $0.10, compared to $0.11 in prior-year period.
Bioventus
Bioventus
Bioventus Revenue by Geographic Location
Revenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Bioventus updated its full year 2022 financial guidance, expecting net sales of $547.5 million to $562.5 million and adjusted EBITDA of $94 million to $104 million. It also introduced Non-GAAP EPS guidance of $0.47 to $0.57.
Positive Outlook
- Net sales of $547.5 million to $562.5 million, representing year-over-year growth of approximately 27% to 31%.
- Adjusted EBITDA of $94 million to $104 million, compared to $80.8 million for the year ended December 31, 2021.
- Non-GAAP EPS of $0.47 to $0.57, compared to $0.75 for the year ended December 31, 2021.
- The company is now providing Non-GAAP EPS guidance in light of the completion of the CartiHeal acquisition on July 12, 2022.
- Guidance reflects management's current expectations regarding the impact of COVID-19 on its business.
Challenges Ahead
- Adjusted EBITDA guidance update from the prior guidance of $94 million to $107 million due to the inclusion of expenses related to CartiHeal.
- COVID-19 pandemic could cause the Company’s future operating results to be different from current expectations, particularly if the impact of the pandemic worsens.
- The company is highly dependent on a limited number of products.
- The severity and duration of the COVID-19 pandemic are outside of the Company’s control.
- The company may be unable to successfully commercialize newly developed or acquired products or therapies in the United States
Revenue & Expenses
Visualization of income flow from segment revenue to net income